These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 15898346)

  • 21. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
    Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease.
    Salenave S; Bernard V; Do Cao C; Guignat L; Bachelot A; Leboulleux S; Droumaguet C; Bry-Gauillard H; Pierre P; Crinière L; Santulli P; Touraine P; Chanson P; Schlumberger M; Maiter D; Baudin E; Young J
    Eur J Endocrinol; 2015 Feb; 172(2):141-9. PubMed ID: 25411236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adrenocortical carcinoma and its treatment with mitotane. Description of a case].
    Parma A; D'Agnolo B
    Minerva Med; 1991 Dec; 82(12):883-8. PubMed ID: 1780099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant mitotane in adrenocortical carcinoma.
    Dickstein G; Shechner C; Nativ O
    N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
    [No Abstract]   [Full Text] [Related]  

  • 25. Hair cortisol measurement in mitotane-treated adrenocortical cancer patients.
    Manenschijn L; Quinkler M; van Rossum EF
    Horm Metab Res; 2014 Apr; 46(4):299-304. PubMed ID: 24627099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
    Demeure MJ; Somberg LB
    Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma.
    Komarowska H; Ruciński M; Fichna M; Bromińska B; Iżycki D; Czarnywojtek A; Ruchała M
    Pol Arch Intern Med; 2019 Aug; 129(7-8):469-475. PubMed ID: 31169262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of mitotane lipid nanocarriers and enantiomers: two-in-one solution to efficiently treat adreno-cortical carcinoma.
    Menaa F; Menaa B
    Curr Med Chem; 2012; 19(34):5854-62. PubMed ID: 22934807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
    Veytsman I; Nieman L; Fojo T
    J Clin Oncol; 2009 Sep; 27(27):4619-29. PubMed ID: 19667279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE
    N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract]   [Full Text] [Related]  

  • 31. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
    Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
    Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
    Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.
    Maiter D; Bex M; Vroonen L; T'Sjoen G; Gil T; Banh C; Chadarevian R
    Ann Endocrinol (Paris); 2016 Oct; 77(5):578-585. PubMed ID: 27063476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
    Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
    Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
    Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
    J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
    Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
    Gonzalez RJ; Tamm EP; Ng C; Phan AT; Vassilopoulou-Sellin R; Perrier ND; Evans DB; Lee JE
    Surgery; 2007 Dec; 142(6):867-75; discussion 867-75. PubMed ID: 18063070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review.
    Advani A; Vaikkakara S; Gill MS; Arun CS; Pearce SH; Ball SG; James RA; Lennard TW; Bliss RD; Quinton R; Johnson SJ
    J Clin Pathol; 2008 Aug; 61(8):939-44. PubMed ID: 18515402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.
    Papewalis C; Fassnacht M; Willenberg HS; Domberg J; Fenk R; Rohr UP; Schinner S; Bornstein SR; Scherbaum WA; Schott M
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):215-22. PubMed ID: 16886963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane.
    Sbiera S; Kendl S; Weigand I; Sbiera I; Fassnacht M; Kroiss M
    Mol Cell Endocrinol; 2019 Jan; 480():36-41. PubMed ID: 30315857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.